THNRAmplify Weight Loss Drug & Treatment ETF
Seeks investment results that generally correspond to the performance of the VettaFi Weight Loss Drug & Treatment Index.
By Amplify ETFs · Launched 2024
Annual Cost
0.59%
#3,222 of 6,040 · average
Fund Size
$5M
#5,276 of 6,040 · small
Return (1Y)
+11.9%
Track Record
2 years
#3,502 of 6,040 · seasoned
Performance
Total-return NAV · USDGrowth of $10,000
$11,173+11.7%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundAsset class
EquityRegion
GlobalStrategy
Index tracking
Sector
Health careFocus
Obesity & GLP-1
Index tracked
VettaFi Weight Loss Drug & Treatment Index
Holdings
By weightConcentration
Top 10 holdings = 66.5% of fundconcentrated
Novo Nordisk A/S
11.9%
Eli Lilly & Co
11.6%
Regeneron Pharmaceuticals Inc
6.8%
Amgen Inc
6.3%
Chugai Pharmaceutical Co Ltd
6.0%
CSPC Pharmaceutical Group Ltd
5.0%
Arrowhead Pharmaceuticals Inc
5.0%
AbbVie Inc
4.8%
AstraZeneca PLC
4.7%
Pfizer Inc
4.6%
Asset allocation
Stocks
99.3%
Cash
0.5%
Other
0.2%
By sector
Healthcare
100.0%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
19.6%Moderate
Year-on-year price swings
Max drawdown
-32.5%Severe
Worst peak-to-trough loss
Sharpe (3Y)
Unavailable
Needs 3+ years of history
Sortino (3Y)
Not yet
Needs 3+ years of history
Listing
- Exchange
- NYSE Arca
Full fund details
- Objective
- Seeks investment results that generally correspond to the performance of the VettaFi Weight Loss Drug & Treatment Index.
- Strategy
- Invests at least 80% of net assets in securities that comprise the VettaFi Weight Loss Drug & Treatment Index using a replication strategy, with the option for representative sampling. Focuses on global health care companies involved in weight loss drug development, including pharmaceutical manufacturers and telehealth providers.
- Inception date
- May 20, 2024
- Fund family
- Amplify ETFs
Similar funds
Same asset class, closest by strategy & exposureNext steps
Save THNR to compare it with other funds, or start building a portfolio.
Data updated on 2026-09-18